Faculty Collaboration Database

The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. Leuk Lymphoma 1996 Sep;23(1-2):1-9

Date

09/01/1996

Pubmed ID

9021679

DOI

10.3109/10428199609054795

Scopus ID

2-s2.0-0029803984 (requires institutional sign-in at Scopus site)   13 Citations

Abstract

Tumor relapse remains a major obstacle to the success of allogeneic bone marrow transplantation (BMT) as a treatment for leukemia. Due to limited treatment options, the outlook for most patients that relapse following allogeneic BMT has been poor. The infusion of normal immunocompetent leukocytes from the original marrow donor has become a promising new option for treating/preventing leukemia relapse in allogeneic BMT recipients. This form of treatment has often been referred to as donor leukocyte infusion (DLI) therapy. Our laboratory is using murine models of allogeneic BMT to address important unresolved issues regarding DLI therapy in an effort to make the treatment more effective. These include identification of the antileukemic effector cells, augmentation of the antileukemic effect, and understanding why graft-versus-host-disease (GVHD) is less severe than anticipated. This article reviews our work in murine models of DLI and introduces our current working hypotheses concerning DLI therapy.

Author List

Johnson BD, Hanke CA, Truitt RL

Author

Bryon D. Johnson PhD Adjunct Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Animals
Blood Donors
Bone Marrow Transplantation
Combined Modality Therapy
Graft vs Host Disease
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukocyte Transfusion
Mice
Recurrence
Transplantation, Homologous